AUTHORS
Jan Philipp Bewersdorf, MD, Rong Wang, PhD2, Rohan K Achar, MD, MSCR3, Henry Dumke, MD4, Lourdes Mendez, MD, Ph D5, Alain Mina, MD6, Luis E. Aguirre, MD, MPH7, Maximilian Stahl, MD8, Amer M. Zeidan, MD9, Xiaomei Ma, MD, PhD10, Nikolai Podoltsev, MD, PhD11
AFFILIATIONS
1 Yale University School of Medicine, New Haven, Connecticut, United States
2 Yale University School of Public Health, New Haven, Connecticut, United States
3 Yale University School of Medicine, New Haven, Connecticut, United States
4 Yale University School of Medicine, New Haven, Connecticut, United States
5 Yale University School of Medicine, New Haven, Connecticut, United States
6 Yale University School of Medicine, New Haven, Connecticut, United States
7 Yale University School of Medicine, New Haven, Connecticut, United States
8 Yale University School of Medicine, New Haven, Connecticut, United States
9 Yale University School of Medicine, New Haven, Connecticut, United States
10 Yale University School of Public Health, New Haven, Connecticut, United States
11 Yale University School of Medicine, New Haven, Connecticut, United States
ABSTRACT
Introduction: A better understanding of the pathogenesis of acute myeloid leukemia (AML) has led to the development of several targeted therapies including FLT3, IDH1/2, and menin inhibitors. It is essential to assess real-world patterns of molecular testing to enable optimal use of these novel therapies.
Methods: We used the Flatiron Health Research Database, an electronic health record-derived deidentified database from 220+ oncology practices in the United States, to select adult patients (pts) (≥18 years) newly diagnosed with AML during 2014-2024 who underwent molecular testing by next-generation sequencing (NGS) and/or PCR within +/- 30 days of diagnosis. Pts with acute promyelocytic leukemia (APL) were excluded. Since the approval of the FLT3 inhibitor midostaurin in combination with intensive induction chemotherapy for pts with newly diagnosed FLT3-mutant AML in 2017 marked the advent of individualized, molecularly informed treatment for pts with AML, we also performed subgroup analyses for pts diagnosed during 2018-2024. We conducted multivariable logistic and Cox proportional hazards regression analyses to identify predictors of undergoing molecular testing and variables associated with overall survival (OS), respectively. OS was calculated from time of AML diagnosis to death with censoring at the last follow up in the Flatiron database.
Results: Among 11,165 pts with newly diagnosed non-APL AML, 8,089 (72.4%) underwent molecular testing (18.4% with both NGS and PCR, 24.8% NGS only, 18.0% PCR only and 11.2% with unknown type). Testing increased over time from 54.7% in 2014 to 85.1% in 2024 (ptrend <0.01). Multivariable analysis showed that the odds of testing were higher among pts residing in neighborhoods with higher socioeconomic status (odds ratios [ORs] range 1.21 for quintiles 3rd-5th vs. 1st, all p values = 0.02). Conversely, lower molecular testing odds were associated with older age at diagnosis (50-64 years: OR=0.79, 95% CI [confidence interval]: 0.66-0.94, p=0.01; 65-74 years: OR=0.55, 95% CI: 0.46-0.67, p<0.01; ≥75 years: OR=0.35, 95% CI: 0.29-0.41, p<0.01; reference: <50 years), as well as being Hispanic (OR=0.72, 95% CI: 0.59-0.88, p<0.01) compared to being non-Hispanic White.
Median OS was 0.97 (95% CI: 0.93-1.00) years and was longer with molecular testing than without (1.14 years [95% CI: 1.09-1.19] vs. 0.59 years [95% CI: 0.54-0.65], p<0.01). After adjusting for patient sociodemographic and clinical factors, receipt of molecular testing was associated with improved OS and lower risk of death (hazard ratio [HR] = 0.70, 95% CI: 0.66-0.74, p<0.01). Other factors associated with improved OS included being Asian (compared with non-Hispanic White, HR=0.81, 95% CI: 0.67-0.98, p=0.03), Hispanic ethnicity (compared with non-Hispanic White, HR=0.87, 95% CI: 0.77-0.98, p=0.02), later diagnosis year (HR=0.99 for each year, 95% CI: 0.98-1.00, p=0.02), and residence in neighborhoods with higher socioeconomic status (compared with 1st quintile, 4th quintile: HR=0.87, 95% CI: 0.80-0.95, p<0.01; 5th quintile: HR=0.85, 95% CI: 0.78-0.92, p<0.01). On the other hand, older age (50-64 years: HR=1.78, 95% CI: 1.61-1.98, p<0.01; 65-74 years: HR=2.84, 95% CI: 2.56-3.14, p<0.01; ≥75 years: HR=4.52, 95% CI: 4.09-5.01, p<0.01; reference: <50 years) and male sex (HR=1.06, 95% CI: 1.02-1.12, p=0.01) were associated with inferior OS.
Findings were similar in sensitivity analyses of pts diagnosed during 2018-2024.
Conclusion: The percentage of newly diagnosed AML pts undergoing molecular testing has increased over time but remains suboptimal, with persistent disparities observed among older pts and those from racial and ethnic minority or economically disadvantaged groups. Ensuring universal and equitable access to molecular testing is critical, as testing is associated with improved OS.
DISCLOSURES
Jan Philipp Bewersdorf, MD: No relevant conflicts of interest to declare.